CLOs on the Move

Spryance Inc

www.spryance.com

 
Spryance Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Ashley Glen Assisted Living

Ashley Glen Assisted Living is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fitness Connection

This website is for sale! fitnessconnectionusa.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, fitnessconnectionusa.com has it all. We hope you find wha...

Fifth Eye Inc

Fifth Eye`s early warning system continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods.

Ice Biotech

Ice Biotech, Inc. is a Dundas, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.